APA

Cohen A. D., Luger S. M., Sickles C., Mangan P. A., Porter D. L., Schuster S. J., Tsai D. E., Nasta S., Gewirtz A. M. & Stadtmauer E. A. (20030711). Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease. : Bone marrow transplantation.

Chicago

Cohen A D, Luger S M, Sickles C, Mangan P A, Porter D L, Schuster S J, Tsai D E, Nasta S, Gewirtz A M and Stadtmauer E A. 20030711. Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease. : Bone marrow transplantation.

Harvard

Cohen A. D., Luger S. M., Sickles C., Mangan P. A., Porter D. L., Schuster S. J., Tsai D. E., Nasta S., Gewirtz A. M. and Stadtmauer E. A. (20030711). Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease. : Bone marrow transplantation.

MLA

Cohen A D, Luger S M, Sickles C, Mangan P A, Porter D L, Schuster S J, Tsai D E, Nasta S, Gewirtz A M and Stadtmauer E A. Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease. : Bone marrow transplantation. 20030711.